Hostname: page-component-cb9f654ff-w5vf4 Total loading time: 0 Render date: 2025-08-30T05:58:56.948Z Has data issue: false hasContentIssue false
  • English
  • Français

Controlled Trial of P2647 in Elderly Psychiatric Patients

Published online by Cambridge University Press:  29 January 2018

Alan R. Dabbs  and
Hugh F. Paterson
Alan R. Dabbs
Affiliation:
Oakwood Hospital, Maidstone
Hugh F. Paterson
Affiliation:
Oakwood Hospital, Maidstone
Get access Rights & Permissions [Opens in a new window]

Extract

Claimed by the manufacturers as pharmacologically unique, benzquinamide (P2647) is structurally related to reserpine, and to a lesser degree, chlorpromazine (1). It has been demonstrated as markedly suppressing conditioned avoidance responses in animals without influencing the release of central amines, e.g. norepinephrine and serotonin. Animal studies have suggested that this drug is the least sedating of the benzoquinolizine derivatives, acts rapidly and is non-toxic at the recommended dosage levels.

Information

Type
Research Article
Information
The British Journal of Psychiatry , Volume 109 , Issue 459 , March 1963 , pp. 300 - 302
Copyright
Copyright © Royal College of Psychiatrists, 1963 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1. Data from Pfizer Ltd., Sandwich, Kent. Google Scholar
2. Feldman, P. E., Psychosomatics, March, 1962, 148–151.Google Scholar
3. Smith, M. E., Amer. J. Psychiat., 1962, 118, 937–938.CrossRefGoogle Scholar
Submit a response

eLetters

No eLetters have been published for this article.